Walk into any functional medicine conference in 2024 and you will hear the same three letters more than almost any others: NAD. Not because it is fashionable — though it is — but because the underlying biology has finally caught up with the marketing. Over the past decade, a convergence of mitochondrial research, sirtuin biology, and translational aging science has positioned nicotinamide adenine dinucleotide as one of the most clinically actionable targets in longevity medicine. For clinic owners and medical directors, the question is no longer whether NAD+ restoration belongs in your protocol stack. It is which form, which dose, which delivery route, and which patient population gives you the strongest clinical and economic return.
This article is written for practitioners who already understand that 'anti-aging' is a marketing term and that real longevity intervention is about preserving cellular function. If your patients are presenting with metabolic dysfunction, post-viral fatigue, perimenopausal energy collapse, or simply the kind of cognitive fog that arrives somewhere around age 45 and never quite leaves — NAD+ biology is part of that conversation. Here is what the research actually says, and how to think about integrating it into a serious clinical practice.
What Is NAD+ and Why Does It Decline?
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. It exists in two interconvertible forms — oxidized (NAD+) and reduced (NADH) — and serves as the central electron carrier in cellular respiration. Without sufficient NAD+, mitochondria cannot efficiently generate ATP through oxidative phosphorylation. That alone would make it interesting. What makes it indispensable is the second role: NAD+ is the obligate substrate for an entire class of enzymes that regulate aging itself.
Three enzyme families consume NAD+ as substrate: the sirtuins (SIRT1–SIRT7), which regulate DNA repair, mitochondrial biogenesis, and circadian metabolism; the PARPs (poly-ADP-ribose polymerases), which respond to DNA damage; and CD38, an ectoenzyme that increases dramatically with age and inflammation. The problem is arithmetic. As CD38 expression rises and DNA damage accumulates, NAD+ consumption accelerates at exactly the same time that biosynthetic capacity declines. Tissue NAD+ levels in humans drop by an estimated 50% between ages 40 and 60 in skin, brain, liver, and skeletal muscle.
The downstream consequences map almost perfectly onto what we colloquially call 'aging': mitochondrial dysfunction, impaired DNA repair, chronic low-grade inflammation, insulin resistance, sarcopenia, and neurocognitive decline. This is why NAD+ restoration is not a single intervention — it is a leverage point that touches nearly every hallmark of biological aging.
The Precursor Landscape: NMN, NR, and Direct NAD+
NAD+ itself is a large, charged molecule with poor oral bioavailability and limited cellular uptake. For decades this was considered the dead end of the field. The breakthrough came with the recognition that NAD+ can be synthesized intracellularly from smaller precursors via the salvage pathway. Two precursors have dominated the research landscape: nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).
NR enters cells via nucleoside transporters and is converted to NMN by NRK1/NRK2 kinases, then to NAD+ by NMNAT enzymes. NMN, one biosynthetic step closer to NAD+, was long thought to require dephosphorylation to NR before cellular uptake — until the identification of Slc12a8 as a direct NMN transporter in the small intestine reframed the conversation. Both precursors have demonstrated the ability to raise tissue NAD+ in mammalian models, and both have moved into human clinical trials with measurable pharmacokinetics.
For clinical practitioners, the practical distinction matters less than the trade space: oral precursors are convenient and well-tolerated but subject to first-pass metabolism; subcutaneous and intramuscular NAD+ protocols achieve higher peak concentrations but require injection; intravenous NAD+ delivers the most aggressive elevation but is time- and resource-intensive. Each route has a clinical niche.
The Research: What the Data Actually Shows
Preclinical evidence for NAD+ restoration is, frankly, overwhelming. In rodent models, NMN and NR supplementation has been shown to improve insulin sensitivity, restore mitochondrial function in aged muscle, enhance vascular endothelial function, improve cognitive performance in models of neurodegeneration, and extend healthspan markers. The mechanistic story is internally consistent: raise NAD+, restore sirtuin activity, recover mitochondrial output.
Human data is more measured but increasingly substantive. Multiple phase I and phase II trials of oral NR have demonstrated dose-dependent elevation of whole-blood NAD+ — often in the range of 40–90% above baseline at clinically relevant doses — with a favorable safety profile across several weeks of dosing. Trials of oral NMN have shown similar pharmacokinetic signals, with emerging evidence of improvements in aerobic capacity, walking distance, and insulin sensitivity in older adults. Effect sizes are modest but reproducible, and importantly, the safety signal across the precursor literature remains clean.
Where the field has been most disciplined is in distinguishing biomarker change from clinical outcome. Raising NAD+ is not, in itself, a clinical endpoint. The harder question — does NAD+ restoration translate into reduced incidence of age-related disease in humans — remains under active investigation. Early data indicates promise in metabolic, cardiovascular, and neurocognitive domains, but practitioners should be precise about what the evidence does and does not yet support.
The most defensible clinical framing in 2024: NAD+ precursors reliably elevate tissue NAD+ in humans, are well-tolerated at studied doses, and show early signals of functional benefit in specific populations. They are not a longevity guarantee. They are a mechanistically grounded intervention with an unusually strong preclinical-to-clinical translation arc.
Clinical Considerations: How Practitioners Are Using NAD+ Protocols
Among the functional medicine and metabolic clinics we work with, NAD+ protocols have settled into roughly four use cases. Understanding these archetypes is more useful than memorizing dosing tables, because the clinical context drives the protocol.
1. Metabolic and Mitochondrial Support
Patients with insulin resistance, early type 2 diabetes, NAFLD, or post-viral mitochondrial dysfunction represent perhaps the cleanest research-protocol population. The mechanistic rationale is direct: restore NAD+, support SIRT1 and SIRT3 activity, improve mitochondrial substrate handling. Oral NMN or NR at 250–1,000 mg daily is the most studied entry point. Subcutaneous NAD+ protocols are often layered in for patients with severe fatigue or documented mitochondrial markers.
2. Cognitive and Neurological Research Protocols
Practitioners studying cognitive complaints, post-COVID neurocognitive symptoms, or early neurodegenerative concerns often favor intravenous or subcutaneous NAD+ for higher CNS exposure. Protocols vary widely; common research dosing ranges from 100–500 mg per session, titrated for tolerability. Flushing, nausea, and chest tightness during rapid IV infusion are well-documented and dose-dependent — slower infusion rates dramatically reduce these effects.
3. Performance and Recovery
Athletes and high-performing executives represent a self-selecting population willing to invest in optimization protocols. Here, oral precursors paired with periodic injectable NAD+ are common. The clinical conversation should be honest: performance benefits in healthy adults are real but modest, and the strongest evidence remains in deficiency-recovery contexts rather than supraphysiologic enhancement.
4. Longevity and Healthspan Research
This is the patient who has read the literature, tracks their own biomarkers, and is presenting to your clinic specifically asking about NAD+. They deserve a sophisticated conversation: biomarker testing (whole-blood NAD+, methylation clocks, inflammatory markers), a protocol matched to their baseline, and clear expectations about what is measurable versus aspirational.
Across all four use cases, three clinical principles recur. First, baseline measurement matters — NAD+ is one of the few longevity interventions where you can actually quantify the target. Second, combination protocols (precursors plus methyl donor support, plus sirtuin activators where appropriate) are increasingly favored over monotherapy. Third, the dose-response curve plateaus; more is not better, and chasing supraphysiologic NAD+ levels has no demonstrated benefit and theoretical risks around methylation depletion.
What to Look for in a Source
The NAD+ precursor market has expanded faster than its quality control. For licensed practitioners sourcing research-grade material for physician-supervised clinical research protocols, three non-negotiables apply.
First, cGMP manufacturing. NMN and NR are stable molecules under proper conditions but degrade in the presence of heat, moisture, and certain excipients. A supplier without documented cGMP manufacturing cannot guarantee what is actually in the vial six months after production. Ask for the manufacturing facility certification, not just a marketing claim.
Second, third-party certificates of analysis (COA) for every lot. The COA should include identity confirmation (typically HPLC or LC-MS), purity (≥98% is the practical floor for research-grade material), and heavy metals, residual solvents, and endotoxin testing for any injectable formulation. If a supplier cannot produce a lot-specific COA on request, that is the entire conversation.
Third, supply chain transparency. The NAD+ precursor space has been particularly susceptible to material being relabeled multiple times between synthesis and final sale. A serious clinical supplier should be able to tell you where the active pharmaceutical ingredient was synthesized, how it was tested on receipt, and how the finished product was formulated and filled. Vague answers here correlate strongly with vague answers everywhere else.
Why This Matters for Your Practice
The business case for integrating NAD+ protocols into a functional medicine, metabolic, or longevity-focused practice is unusually strong, and worth examining honestly. Three factors converge.
Patient demand is already there. Search volume for NAD+, NMN, and related terms has grown more than tenfold over the past five years. Patients are not asking whether NAD+ is real — they are asking which clinic in their city offers it and which protocol is right for them. If your practice does not have a credible answer, they will find one that does, and increasingly that competitor will be a medical spa with a slicker website and a less rigorous clinical framework.
Recurring revenue dynamics are favorable. Unlike one-time aesthetic procedures, NAD+ protocols are inherently longitudinal. Oral precursor regimens are monthly; injectable protocols are weekly to monthly; IV protocols often follow a loading-and-maintenance schedule. The patient who enters a well-designed NAD+ protocol is engaging with your clinic on a recurring cadence for months to years, which compounds both clinical outcomes and lifetime patient value.
Clinical differentiation is meaningful. The clinics building durable longevity practices are not the ones offering the longest menu — they are the ones that can articulate, in clinical terms, why their protocols are designed the way they are. NAD+ is a place where a serious practice can demonstrate genuine expertise: explaining the precursor landscape, matching protocol to phenotype, measuring response, and adjusting over time. That is what distinguishes a longevity clinic from a wellness storefront.
The practitioners who will own the longevity category over the next decade are the ones building protocols on defensible biology, sourcing from suppliers who can document what is in the bottle, and having honest clinical conversations about what the evidence supports. NAD+ restoration is not the whole story. But it is one of the few interventions where the mechanism, the human data, the safety profile, and the patient demand all point in the same direction. For a serious clinical practice, that combination is rare enough to take seriously.